Skip to main content
main-content

24.01.2018 | T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) | Ausgabe 1/2018

Current Hematologic Malignancy Reports 1/2018

NK/T Cell Lymphoma: Updates in Therapy

Zeitschrift:
Current Hematologic Malignancy Reports > Ausgabe 1/2018
Autor:
Ritsuro Suzuki
Wichtige Hinweise
This article is part of the Topical Collection on T Cell and Other Lymphoproliferative Malignancies

Abstract

Purpose of Review

Extranodal NK/T cell lymphoma (ENKL), nasal type, is a highly aggressive lymphoma which used to show a poor clinical outcome. Expression of P-glycoprotein on lymphoma cells of ENKL is a major reason for the refractoriness to conventional chemotherapy containing anthracycline. However, recent innovative approaches have improved the outcome and prognosis of ENKL. The purpose of this review is to summarize the proceedings of treatment.

Recent Findings

Concurrent chemoradiotherapy containing platinum and several drugs including L-asparaginase, methotrexate, and alkylators shows excellent outcomes for the limited-stage ENKL. SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide) or other L-asparaginase-containing therapy is promising for advanced-stage ENKL, followed by either autologous or allogeneic hematopoietic stem cell transplantation. Anti-PD-1 or other immunological checkpoint inhibitors are recently reported to be effective for relapsed/refractory ENKL thought to be due to EBV-driven upregulation of PD-L1 expression.

Summary

The prognosis of ENKL is therefore improving by the introduction of these strategies. The 5-year overall survival (OS) rate of limited stage was 63.2% [95% confidence interval (CI), 55.3 to 70.0%] before 2010, but was 79.4% (95% CI, 66.9 to 87.6%) in 2010 or after. However, there still exists a room for improvement, particularly for advanced-stage patients. The 2-year OS of advanced ENKL was 30.3% (95% CI, 19.5 to 41.7%) before 2010, but was 40.5% (95% CI, 24.8 to 55.8%) in 2010 or after. Optimal treatment scheme should further be explored.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Current Hematologic Malignancy Reports 1/2018 Zur Ausgabe

T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

Updates of Peripheral T Cell Lymphomas Based on the 2017 WHO Classification

T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)

Stem Cell Transplantation (R Maziarz, Section Editor)

Twitter Use in the Hematopoietic Cell Transplantation Community

T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas—Implications for Therapy

  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise